Russian Heart Failure Journal 2011year Expert Consensus Document on Highly Purified Omega-3 Fatty Acids 90% in the treatment and prophylactic of Congestive Heart Failure


To access this material please log in or register

Register Authorize
2011/

Expert Consensus Document on Highly Purified Omega-3 Fatty Acids 90% in the treatment and prophylactic of Congestive Heart Failure

Expert Consensus Document (June 2011)

Keywords:

DOI: 10.18087/ rhfj.2011.4.1577

  1. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Е. Хроническая сердечная недостаточность. Избранные лекции по кардиологии. – М.: «Гэотар-Медиа», 2006. – 432 с.
  2. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  3. Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin i in older patients with systolic heart failure. N Engl J Med. 2007;357 (22):2248–2261.
  4. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc. Surg. 2007;45 (4):645–654.
  5. Мареев В. Ю. Аспирин при хронической сердечной недостаточности. Взаимодействие аспирина с основными средствами лечения декомпенсации. Журнал Сердечная Недостаточность. 2003;4 (19):153–157.
  6. Tavazzi L, Maggioni AP, Marchioli R et al. Gissi-Hf Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372 (9645):1231–1239.
  7. Packer D, Prutkin J, Hellkamp A et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation. 2009;120 (22):2170–2176.
  8. Køber L, Torp-Pedersen C, McMurray JJ et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358 (25):2678–2687.
  9. Krum H, Carson P, Farsang C et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail. 2004;6 (7):937–945.
  10. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354 (9177):447–455.
  11. Yamagishi K, Iso H, Date C et al. Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women the JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk) Study. J Am Coll Cardiol. 2008;52 (12):988–996.
  12. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372 (9645):1223–1230.
  13. Ghio S, Scelsi L, Latini R et al. for the GISSI-HF investigators. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. Eur J Heart Fail. 2010;12 (12):1345–1353.
  14. Nodari S, Triggiani M, Campia U et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2011;57 (7):870–879.
Expert Consensus Document (June 2011). Expert Consensus Document on Highly Purified Omega-3 Fatty Acids 90% in the treatment and prophylactic of Congestive Heart Failure. Russian Heart Failure Journal. 2011;12(4):244-246.

To access this material please log in or register

Register Authorize
Ru En